Title:Macrophage Migration Inhibitory Factor - A Favorable Marker in Inflammatory Diseases?
VOLUME: 25 ISSUE: 5
Author(s):Johannes Hertelendy, Georg Reumuth, David Simons, Christian Stoppe, Bong-Sung Kim, Jan-Philipp Stromps, Paul C. Fuchs, Jurgen Bernhagen, Norbert Pallua and Gerrit Grieb*
Affiliation:Department of Plastic Surgery and Hand Surgery, Burn Center, Medical Faculty, RWTH Aachen University, Pauwelsstrasse 30, 52074 Aachen, Department of Plastic Surgery and Hand Surgery, Gemeinschaftskrankenhaus Havelhoehe, Teaching Hospital of the Charité Berlin, Kladower Damm 221, 14089 Berlin, Department of Plastic Surgery and Hand Surgery, Burn Center, Medical Faculty, RWTH Aachen University, Pauwelsstrasse 30, 52074 Aachen, Department of Anesthesiology, Medical Faculty, RWTH Aachen University, Pauwelsstrasse 30, 52074 Aachen, Department of Plastic Surgery and Hand Surgery, Burn Center, Medical Faculty, RWTH Aachen University, Pauwelsstrasse 30, 52074 Aachen, Department of Plastic Surgery and Hand Surgery, Burn Center, Medical Faculty, RWTH Aachen University, Pauwelsstrasse 30, 52074 Aachen, Department of Plastic Surgery and Hand Surgery, Burn Center, University of Witten/ Herdecke, Ostmerheimerstrasse 200, 51109 Cologne, Munich Cluster for Systems Neurology (SyNergy), Feodor-Lynen-Strasse 17, 81377 Munich, Department of Plastic Surgery and Hand Surgery, Burn Center, Medical Faculty, RWTH Aachen University, Pauwelsstrasse 30, 52074 Aachen, Department of Plastic Surgery and Hand Surgery, Burn Center, Medical Faculty, RWTH Aachen University, Pauwelsstrasse 30, 52074 Aachen
Keywords:MIF, biomarker, infectious disease, autoimmune disease, cytokine, CD74, CXCR.
Abstract:Background: Macrophage migration inhibitory factor (MIF) was firstly described in the
1960s as a pleiotropic cytokine affecting a variety of immune cells. Different physiological functions
mainly involving inflammatory reactions such as chemokine-like function and regulating systemic
stress responses have been reported.
Objective: In several clinical studies the use of MIF as a biomarker has been investigated promising
support for diseases with an inflammatory aspect such as sepsis, systemic infections and autoimmune
diseases. This article in detail reviews clinical data and evaluates the function as biomarker focusing
on inflammatory and autoimmune diseases.
Conclusion: Recent studies suggest MIF to be a marker for different inflammatory diseases and might
serve as therapeutic target in the future.
